Table 3.
Period of SGA use | CKD cases (n=3411) | Controls (n=10 233) |
OR (95% CI) | P value | AOR* (95% CI) | P value |
Cumulative SGA use | ||||||
Non-users | 303 | 1304 | 1 | 1 | ||
0<period≤ 90 | 177 | 552 | 1.38 (1.12 to 1.71) | 0.0026 | 1.20 (0.95 to 1.51) | 0.1247 |
90<period≤ 180 | 92 | 241 | 1.65 (1.26 to 2.16) | 0.0003 | 1.42 (1.06 to 1.91) | 0.0208 |
180<period≤ 1000 | 409 | 1271 | 1.39 (1.17 to 1.64) | 0.0001 | 1.19 (0.99 to 1.43) | 0.0654 |
1000>period | 2430 | 6865 | 1.53 (1.34 to 1.75) | <0.0001 | 1.30 (1.13 to 1.51) | 0.0004 |
Cumulative clozapine use (days) | ||||||
Non-users | 2318 | 7215 | 1 | 1 | ||
0<period≤ 90 | 183 | 351 | 1.63 (1.35 to 1.96) | <0.0001 | 1.48 (1.20 to 1.81) | 0.0002 |
90<period≤180 | 49 | 140 | 1.09 (0.79 to 1.52) | 0.6057 | 0.91 (0.63 to 1.32) | 0.6281 |
180<period≤1000 | 178 | 549 | 1.01 (0.85 to 1.20) | 0.9091 | 0.94 (0.77 to 1.14) | 0.5099 |
1000>period | 683 | 1978 | 1.08 (0.98 to 1.19) | 0.1456 | 1.14 (1.02 to 1.27) | 0.0181 |
Cumulative olanzapine use (days) | ||||||
Non-users | 2046 | 6465 | 1 | 1 | ||
0<period≤90 | 396 | 1018 | 1.23 (1.09 to 1.40) | 0.0012 | 1.18 (1.02 to 1.35) | 0.0225 |
90<period≤180 | 156 | 344 | 1.44 (1.18 to 1.75) | 0.0003 | 1.37 (1.11 to 1.70) | 0.0039 |
180<period≤1000 | 401 | 1038 | 1.22 (1.08 to 1.39) | 0.0017 | 1.15 (1.00 to 1.32) | 0.0561 |
1000>period | 412 | 1368 | 0.95 (0.85 to 1.08) | 0.4401 | 1.05 (0.92 to 1.19) | 0.4954 |
Cumulative quetiapine use (days) | ||||||
Non-users | 1669 | 6198 | 1 | 1 | ||
0<period≤90 | 399 | 967 | 1.54 (1.35 to 1.75) | <0.0001 | 1.36 (1.19 to 1.57) | <0.0001 |
90<period≤180 | 147 | 356 | 1.54 (1.26 to 1.88) | <0.0001 | 1.27 (1.02 to 1.58) | 0.0358 |
180<period≤1000 | 534 | 1180 | 1.69 (1.50 to 1.89) | <0.0001 | 1.48 (1.30 to 1.68) | <0.0001 |
1000>period | 662 | 1532 | 1.61 (1.45 to 1.79) | <0.0001 | 1.44 (1.28 to 1.62) | <0.0001 |
Cumulative zotepine use (days) | ||||||
Non-users | 2292 | 7375 | 1 | 1 | ||
0<period≤90 | 319 | 743 | 1.38 (1.20 to 1.59) | <0.0001 | 1.26 (1.08 to 1.47) | 0.0038 |
90<period≤180 | 120 | 265 | 1.46 (1.17 to 1.82) | 0.0008 | 1.27 (0.99 to 1.63) | 0.0592 |
180<period≤1000 | 310 | 770 | 1.30 (1.13 to 1.49) | 0.0003 | 1.16 (1.00 to 1.36) | 0.0572 |
1000>period | 370 | 1080 | 1.11 (0.97 to 1.26) | 0.1240 | 1.00 (0.87 to 1.15) | 0.9854 |
Cumulative risperidone use (days) | ||||||
Non-users | 896 | 3056 | 1 | 1 | ||
0<period≤90 | 396 | 1078 | 1.26 (1.09 to 1.44) | 0.0012 | 1.14 (0.98 to 1.33) | 0.0927 |
90<period≤180 | 207 | 511 | 1.39 (1.16 to 1.66) | 0.0003 | 1.26 (1.03 to 1.53) | 0.0220 |
180<period≤1000 | 733 | 2028 | 1.24 (1.10 to 1.38) | 0.0002 | 1.12 (0.99 to 1.26) | 0.0845 |
1000<period | 1179 | 3560 | 1.13 (1.03 to 1.25) | 0.0148 | 1.10 (0.99 to 1.23) | 0.0756 |
*Adjusted for diabetes mellitus, congestive heart failure, myocardial infarction, stroke, hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, hypertension and obesity.
AOR, adjusted OR; CKD chronic kidney disease; SGA, second-generation antipsychotic.